About us

Intervacc develop novel veterinary vaccines and the pipeline is based on new technology using recombinant proteins rather than attenuated live strains found in conventional vaccines. This results in vaccines with much lower incidence of side effects usually seen with conventional vaccines, something we take pride in as it greatly contributes to an improved animal welfare.

A strong team with extensive knowlegde in Animal Health Care.

The company have its own sales organisation within the Nordic countries and the Baltic states through its subsidiary Nordvacc Läkemedel AB. Nordvacc have a long standing history of supplying this market with animal welfare products for over 30 years and the majority of  the annual turnover is based on revenue from veterinary vaccines.

Our ISO-certified and well-renowned subsidiary the Mybac-Vettech laboratory, offers bacteriological and mycological analyses on the Swedish market.

Intervacc and its subsidiaries have, in addition to a network of consultants, 13 permanently employed coworkers at Hägersten outside Stockholm proper and in Denmark, Latvia, Lithuania, and Finland.

Together we comprise a strong force of skilled and enthusiastic coworkers committed to animal welfare.

Investor presentation August 27, 2018

CSO Jan-Ingmar Flock presents Intervacc and the development of a new generation of vaccines within animal health. Strangvac® – our vaccine against equine strangles is first and the development of two other vaccines INV274 and INV412 continues with new funding from Eurostars-2/Horizon 2020 and Vinnova.

Here you can see the recorded and transcribed presentation which is about 23 minutes including the following Q&A.